← Back to patent-cliff list
Nacresertib
Tier C — Watch / tradeNacresertib
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：IRAK4
Indications (approved)：Rheumatoid arthritis, Psoriasis, 免疫球蛋白a肾病
Regional status
US
Phase I
2025-04-18
EU
-
China
Phase II
2023-06-16
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Nacresertib?
Approved indications include: Rheumatoid arthritis, Psoriasis, 免疫球蛋白a肾病.
When does the Nacresertib patent expire?
No public expiry year is available for Nacresertib yet; this page updates once verified.
How do I get a quote for Nacresertib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03